Sign Up to like & get
recommendations!
1
Published in 2018 at "Nature Biotechnology"
DOI: 10.1038/nbt.4249
Abstract: Sage Therapeutics Shionogi 90 Sage grants Shionogi exclusive rights in Japan, Taiwan and South Korea to SAGE-217, a next-generation GABAA positive allosteric small-molecule modulator to treat major depressive disorder Skyhawk Therapeutics Celgene 60 Skyhawk grants…
read more here.
Keywords:
exclusive rights;
develop commercialize;
q218 public;
small molecule ... See more keywords